| |
Total
|
Primary infection
|
Secondary infection
|
|---|
|
Plasma
|
ELISA
|
All samples
|
66 % (159/241)
|
95.7 % (66/69)
|
51.1 % (69/135)
|
| | |
DAOF ≤ 3
|
94.4 % (67/71)
|
100 % (29/29)
|
88.6 % (31/35)
|
| | |
DAOF 4–7
|
66.7 % (82/123)
|
93.9 % (31/33)
|
51.4 % (36/70)
|
| | |
DAOF 8–12
|
21.3 % (10/47)
|
85.7 % (6/7)
|
6.7 % (2/30)
|
|
Urine
|
ELISA
|
All samples
|
14.3 % (63/440)
|
18.3 % (23/126)
|
8.1 % (20/246)
|
| | |
DAOF ≤ 3
|
9.9 % (8/81)
|
15.6 % (5/32)
|
2.4 % (1/41)
|
| | |
DAOF 4–7
|
19.2 % (52/271)
|
21.5 % (17/79)
|
12.3 % (19/154)
|
| | |
DAOF 8–12
|
3.4 % (3/88)
|
6.7 % (1/15)
|
0 % (0/51)
|
|
Urine
|
RDT
|
All samples
|
15.5 % (68/440)
|
18.3 % (23/126)
|
10.6 % (26/246)
|
| | |
DAOF ≤ 3
|
11.1 % (9/81)
|
15.6 % (5/32)
|
4.9 % (2/41)
|
| | |
DAOF 4–7
|
21 % (57/271)
|
21.5 % (17/79)
|
15.6 % (24/154)
|
| | |
DAOF 8–12
|
2.3 % (2/88)
|
6.7 % (1/15)
|
0 % (0/51)
|
|
Saliva
|
ELISA
|
All samples
|
24.7 % (72/291)
|
43.5 % (37/85)
|
15.5 % (27/174)
|
| | |
DAOF ≤ 3
|
25.5 % (12/47)
|
41.2 % (7/17)
|
19.2 % (5/26)
|
| | |
DAOF 4–7
|
29.9 % (55/184)
|
46.7 % (28/60)
|
19.4 % (21/108)
|
| | |
DAOF 8–12
|
8.3 % (5/60)
|
25 % (2/8)
|
2.5 % (1/40)
|
|
Saliva
|
RDT
|
All samples
|
20.8 % (60/289) b
|
31 % (26/84) a
|
16.2 % (28/173) a
|
| | |
DAOF ≤ 3
|
14.9 % (7/47)
|
23.5 % (4/17)
|
11.5 % (3/26)
|
| | |
DAOF 4–7
|
25.7 % (47/183) a
|
33.9 % (20/59) a
|
19.4 % (21/108) a
|
| | |
DAOF 8–12
|
10.2 % (6/59) a
|
25 % (2/8)
|
10.3 % (4/39) a
|
- The sensitivity of the different diagnostic tools for NS1 detection in plasma, urine and saliva of DENV-infected patients is presented according to the time of sampling after the onset of the fever and the immune status of the patients
-
DAOF Day After Onset of Fever
-
a One invalid result
-
b Two invalid results
